Onxeo to Present New Preclinical Data at AACR 2021
Confirming the effect of AsiDNA™ on resistance to KRAS inhibitors Introducing OX400, a new generation of PARP interfering cancer drug […]
Onxeo Announces Completion of Patient Enrollment in DRIIV-1b Study and Positive Interim Results
The last patient was treated with AsiDNA™ in combination with carboplatin and paclitaxel in this Phase 1b study in patients […]
Onxeo Receives Notice of Intent to Grant a New Patent Enhancing the Protection in Europe of AsiDNA™ Combined with PARP Inhibitors
This new patent protects the method of use of AsiDNA™ in combination with PARP inhibitors in the treatment of HR-proficient […]
Onxeo Announces Enrollment of First Patient in Phase Ib/II Study Revocan
Revocan is designed to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian cancer […]
Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA™ via Systemic Administration in the United States
This new patent will add to the protection of AsiDNA™ and its related compounds for their use via systemic administration […]
Onxeo Reports Publication of Final Results of DRIIV Phase 1 Dose-Escalation Study of AsiDNA™ in Advanced Solid Tumors in the British Journal of Cancer
DRIIV was instrumental in demonstrating a good safety profile and activity via IV route and in determining the active dose […]
Onxeo Announces Approval of the REVocan Study By Regulatory Authorities
The REVocan study aims to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian […]
New AsiDNA™ e-Poster Now Online at AACR Virtual Meeting 2020
Preclinical Data Confirm the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi by Preventing Regrowth of Death-Tolerant Cells […]
BFM Business Intégrale Bourse : Onxeo, Company of the Day
Interview of Judith Greciet, CEO of Onxeo, following the entry into the capital of Invus, a long-term renowned investor […]
Onxeo to Present New Preclinical Data at AACR 2020 Confirming the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi
Paris (France), Mai 19, 2020 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Onxeo Announces Publication of Preclinical Study Results Comparing Efficacy and Toxicity of olaparib and AsiDNA™ in Frontiers in Oncology
In-vivo Models Showed that Only AsiDNA™ Could Delay Resistance to Carboplatin without Increasing its Toxicity Paris (France), November 13, 2019 […]
Onxeo Enters Clinical Research Agreement with Gustave Roussy to Conduct Clinical Trial of AsiDNA™ for Treatment of Relapsed Ovarian Cancer
The REVOCAN phase 1b/2 study, sponsored by Gustave Roussy, will evaluate the effect of AsiDNA™ on the acquired resistance to […]
Onxeo Receives U.S. Patent and Trademark Office Notice of Allowance for New Patent Protecting Combination of AsiDNA™ with Any PARP Inhibitor for Cancer Treatment
Combination patent to be granted in the U.S. until 2036 Paris (France), November 4, 2019 – 5:45 pm CEST – […]
Onxeo to Present Final Results of DRIIV-1 Phase 1 Study of AsiDNA™ in Advanced Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Positive Safety and Activity Results from DRIIV-1 Led to Initiation of Ongoing DRIIV-1b Phase 1b Study of AsiDNA™ in Combination […]
Onxeo receives EPO Intent-to-Grant Notice for New Patent strengthening European Protection of Compounds sourced from its platON™ Platform
This new patent protects in particular AsiDNA™ and its related compounds for their use in the treatment of cancer, alone […]
Onxeo announces positive intermediate results from the first part of the DRIIV-1b study evaluating AsiDNA™ in combination with chemotherapy
Stabilized disease without tumor progression for two of the three treated patients who are still receiving treatment with AsiDNA™ […]
Onxeo Announces Initiation of DRIIV Phase I Clinical Trial of AsiDNA™ for Treatment of Advanced Solid Tumor
First patient has been dosed with AsiDNA™, Company’s first-in-class DNA Repair Inhibitor Study approved in France and Belgium, and conducted […]
Onxeo Strengthens AsiDNA™ Patent Protection in Europe
Composition of matter patent to be granted in Europe covering AsiDNA™ and more precisely the part related to its DNA sequence […]
Onxeo Announces Positive Preclinical Proof of Concept Results Confirming AsiDNA™ Activity via Systemic Administration
Strong data confirms near-term plan to initiate clinical trial for AsiDNA™, Onxeo’s breakthrough DNA Repair Inhibitor Paris (France), July 05 […]
Onxeo announces compelling preclinical data in combination for its two innovative compounds, AsiDNA™ and belinostat
Results demonstrate a very strong synergistic effect between AsiDNA™, first-in-class DNA break repair inhibitor (DBRi), and histone deacetylase inhibitors (HDACi) […]
Onxeo Introduces platON™, a Proprietary Chemistry Platform of Decoy Oligonucleotides
2 OCT., 2017 PlatON™ will generate new best-in-class DNA-targeting drug candidates starting in 2018 In parallel, the Company advances its […]
Onxeo Establishes Scientific Advisory Board with International Experts in DNA-targeting
Professor Tomas Lindahl, DNA Repair Pioneer and 2015 Nobel Prize laureate, will serve as Chair of the Scientific Advisory Board […]
Onxeo Announces Positive Interim Results from Phase 1 Study of AsiDNA™, a First-In-Class DNA Damage Response Inhibitor
Robust biological target engagement in patient tumor cells confirms the activity of AsiDNA™ when administered intravenously Favorable safety profile with […]
Onxeo announces final positive data from DRIIV-1 Phase 1 Study of AsiDNA™ in Advanced Solid Tumors
Primary safety and activity endpoints met Favorable safety profile, maximum tolerated dose not reached, optimal active dose determined AsiDNA™ induced […]
Onxeo advances development plan for first-in-class signal interfering DNA compound AsiDNA
Near- and mid term expected milestones Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO, “Onxeo” or ”the […]
Onxeo receives USPTO Notice of Allowance for key AsiDNA™ patent, extending IP protection in the U.S. until 2031
Products, including AsiDNA (signal interfering DNA), protected until 2031 with potential extension to 2036 Onxeo’s intellectual property for DNA repair […]
Combination of AsiDNA and PARP Inhibitors Demonstrates Synergistic Effect, Bypasses Genetic Restriction
Preclinical Research Published in Clinical Cancer Research Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative […]
The French Academy of Sciences Awards the Guy Lazorthes Prize to Doctor Marie Dutreix for Her Innovative Research on the Dbait Technology
Since the acquisition of the Dbait technology last February, Onxeo has launched an ambitious clinical development program for AsiDNA™, a first-in-class […]
Radiotherapy, immunotherapy and DNA repair inhibitors: a winning combination towards the oncology of the future
The Institut Curie and Onxeo join forces in this ambitious project that will benefit cancer patients Paris (France), Copenhagen (Denmark), […]
Onxeo receives USPTO Notice of Allowance for a new AsiDNA™-related patent, expanding its IP protection in the U.S.
New patent expands Onxeo’s intellectual property to a large family of compounds related to AsiDNA™ Paris (France), February 13, 2017 […]
Onxeo to Present Data Supporting Three Key Orphan Oncology Assets at AACR Annual Meeting
Preclinical studies of AsiDNA™, Livatag® and Beleodaq® Paris (France), March 21, 2017 – 6 pm CET – Onxeo S.A. (Euronext […]
Onxeo receives EPO Intent-to-Grant Notice for key AsiDNA™ patent
Onxeo receives EPO Intent-to-Grant Notice for key AsiDNA™ patent, extending IP protection in Europe until 2031 Composition of matter patent […]
Onxeo to Present Results of Two Studies Highlighting Potential of AsiDNA™ as Anti-Cancer Treatment at 2018 AACR Annual Meeting
Paris (France), March 15th, 2018 – 7:00 am CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology […]
New Preclinical Results on Onxeo’s AsiDNA™, First-in-Class DNA Repair Inhibitor, Point to Strong Synergy and Reversion of Tumor Resistance when combined to PARP inhibitors
AsiDNA™ combined with olaparib* more than doubled the complete response rate observed with olaparib alone in an in vivo model […]
Onxeo to Present Overview of AsiDNA™ for Treatment of Solid Tumors at DNA Damage Response Therapeutics Summit 2019
Paris, October 18, 2018 – 6:30 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology […]
Onxeo receives EPO Intent-to-Grant Notice for new patent protecting AsiDNA™ in combination with any PARP inhibitor
Combination patent to be granted in Europe until 2036 Paris (France), December 18, 2018 – 8.30 pm CET – […]
Onxeo Announces Identification of Predictive Biomarkers for AsiDNA™, its First-in-Class DNA Damage Response Inhibitor
Biomarkers correlated to tumoral sensitivity to AsiDNA™, supporting personalized medicine approaches A selection tool to screen patients in future clinical […]
Onxeo to Present Five Preclinical Studies Highlighting AsiDNA™ Unique Profile and its clinical potential in Oncology at 2019 American Association for Cancer Research Annual Meeting
Paris (France), February 13, 2019 – 6.00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Onxeo to Present Data supporting Lead Asset AsiDNA™ in 5 Poster Presentations at 2019 American Association for Cancer Research Annual Meeting
Paris (France), March 25, 2019 – 6.00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Onxeo Announces Treatment of First Patient in DRIIV-1b, a Phase 1b Clinical Trial of AsiDNA™ in Combination with Chemotherapy
DRIIV-1b is designed to assess the clinical potential of AsiDNA™ in combination with carboplatin and with carboplatin plus paclitaxel in […]